29494 Federal Register / Vol. 74, No. 118 / Monday, June 22, 2009 / Notices 

Dated: October 1, 2008. 

Janean Chambers, 

Reports Clearance Officer. 

Editorial Note: This document was 

received in the Office of the Federal Register 

on June 17, 2009. 

[FR Doc. E9–14543 Filed 6–19–09; 8:45 am] 

BILLING CODE 4184–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Agency Information Collection 

Activities: Submission for OMB 

Review; Comment Request 

Periodically, the Substance Abuse and 

Mental Health Services Administration 

(SAMHSA) will publish a summary of 

information collection requests under 

OMB review, in compliance with the 

Paperwork Reduction Act (44 U.S.C. 

Chapter 35). To request a copy of these 

documents, call the SAMHSA Reports 

Clearance Officer on (240) 276–1243. 

Proposed Project: Rapid HIV Testing 

Clinical Information Form for the 

Minority AIDS Initiative (MAI) for 

Ethnic and Racial Minorities at Risk for 

Substance Use and HIV/AIDS— 

Reinstatement 

The Substance Abuse and Mental 

Health Services Administration’s 

(SAMHSA) Center for Substance Abuse 

Treatment (CSAT), is requesting an 

OMB review and approval of the 

Minority AIDS Initiative (MAI) Rapid 

HIV Testing Clinical Information Form 

that will be utilized for ethnic and racial 

minority groups at risk for substance use 

and HIV/AIDS that are served by 

CSAT’s TCE–HIV grantees. The MAI 

Rapid HIV Testing Clinical Information 

Form would allow SAMHSA/CSAT to 

collect essential clinical information 

that will be used for quality assurance, 

quality performance, and product 

monitoring on approximately 30,000 

rapid HIV test kits to be provided to 

ethnic and racial minority communities 

at no cost to the recipient provider 

organizations. The MAI Rapid HIV 

Testing Clinical Information Form 

would support quality of care, provide 

adequate clinical and product 

monitoring, and provide appropriate 

safeguards against fraud, waste and 

abuse of Federal funds. SAMHSA’s 

approach would avoid unnecessary 

delay in informing any person 

potentially adversely affected by a test 

kit recall or public health advisory. This 

program is authorized under section 509 

of the Public Health Service (PHS) Act 

[42 U.S.C. 290bb–2]. 

The goals of SAMHSA’s MAI 

initiative are to: (1) Increase the access 

by racial and ethnic minority 

communities to HIV testing, prevention, 

care, and treatment services; (2) 

implement strategies and activities 

specifically targeted to the highest risk 

and hardest-to-serve populations; (3) 

reduce the stigma associated with HIV/ 

AIDS screening through outreach and 

education, and (4) establish 

collaborations or opportunities for 

programs and/or activities to be 

integrated. 

The target populations for the 

initiative are African Americans, 

Hispanic/Latinos, and other racial and 

ethnic minorities that are 

disproportionately impacted by the twin 

epidemics of HIV/AIDS and substance 

abuse. Since 1981 approximately 1.7 

million people are estimated to have 

been infected with HIV in the U.S., and 

more than 1.1 million are estimated to 

be living with HIV/AIDS today. Racial 

and ethnic minorities have been 

disproportionately affected by HIV/ 

AIDS, and represent the majority of new 

AIDS cases (70%), new HIV infections 

(54%), prevalent HIV/AIDS cases (65%), 

and AIDS deaths (72%) (CDC, 2006). 

African Americans have been especially 

affected by HIV/AIDS. More than half of 

all new HIV infections and half of new 

AIDS diagnoses occur in African 

Americans despite their accounting for 

approximately 12% of the U.S. 

population. A similar impact exists 

among Latinos, who represent 14% of 

the U.S. population but account for 20% 

of estimated AIDS diagnoses. Together, 

Asian/Pacific Islanders and American 

Indian/Alaska Natives represent 1%– 

2% of new AIDS diagnoses. 

The spread of HIV disease in the 

United States has been partly fueled by 

the use of illicit drugs. Injection drug 

use (IDU) is directly related to HIV 

transmission through the sharing of 

drug equipment. According to CDC’s 

latest report on 2006 rates, IDUs 

accounted for 12 percent of estimated 

new HIV infections. CDC’s historical 

trend analysis indicates that new 

infections have declined dramatically in 

this population over time and confirm 

the substantial evidence to date of 

success in reducing HIV infections 

among IDUs. Despite these declines, 

rates of HIV and AIDS continue to rise 

among certain groups including men 

who have sex with men, high risk 

heterosexual women and ethnic and 

racial minority groups due to non-IDU 

drugs and alcohol that interfere with 

judgment about sexual and other types 

of behaviors. 

The estimated hour burden is 

presented in the following table: 

Form Number of 

respondents 

Responses/ 

respondent 

Hours/ 

response 

Total hour burden 

Hourly wage 

cost 

($) 

Total hour cost 

$) 

MAI Rapid HIV Testing Clinical Information Form (at Entry) .............................. 20,000 1 .133 2,660 30.00 79,800 

MAI Rapid HIV Testing Clinical Information Form (second test) ........................ 4,000 1 .133 532 30.00 15,960 

Total .................................................. 20,000 ........................ ........................ 3,192 ........................ 95,760 


pwalker on PROD1PC71 with NOTICES
Federal Register / Vol. 74, No. 118 / Monday, June 22, 2009 / Notices 29495 

Written comments and 

recommendations concerning the 

proposed information collection should 

be sent by July 22, 2009 to: SAMHSA 

Desk Officer, Human Resources and 

Housing Branch, Office of Management 

and Budget, New Executive Office 

Building, Room 10235, Washington, DC 

20503; due to potential delays in OMB’s 

receipt and processing of mail sent 

through the U.S. Postal Service, 

respondents are encouraged to submit 

comments by fax to: 202–395–6974. 

Dated: June 15, 2009. 

Elaine Parry, 

Director, Office of Program Services. 

[FR Doc. E9–14556 Filed 6–19–09; 8:45 am] 

BILLING CODE 4162–20–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Eunice Kennedy Shriver National 

Institute of Child Health & Human 

Development; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Child Health and Human Development 

Special Emphasis Panel. Attention 

Trajectories from 5 to 7 Years. 

Date: June 25, 2009. 

Time: 2 p.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6100 

Executive Boulevard Room 5B01, Rockville, 

MD 20852. (Telephone Conference Call). 

Contact Person: Carla T. Walls, PhD, 

Scientific Review Administrator, Division of 

Scientific Review, National Institute of Child 

Health and Human Development, NIH, 6100 

Executive Blvd., Room 5B01, Bethesda, MD 

20892. (301) 435–6898. wallsc@mail.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.864, Population Research; 

93.865, Research for Mothers and Children; 

93.929, Center for Medical Rehabilitation 

Research; 93.209, Contraception and 

Infertility Loan Repayment Program, National 

Institutes of Health, HHS) 

Dated: June 12, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–14497 Filed 6–19–09; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Diabetes, 

Obesity and Endocrine Disorders. 

Date: July 7–8, 2009. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Virtual Meeting). 

Contact Person: Nancy Sheard, SCD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6046–E, 

MSC 7892, Bethesda, MD 20892, 301–435– 

1154, sheardn@csr.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Tumor 

Immunology and Genetic Pathways in 

Cancer. 

Date: July 9, 2009. 

Time: 10 a.m. to 12 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Malaya Chatterjee, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6192, 

MSC 7804, Bethesda, MD 20892, 301–451– 

0131, chatterm@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Gametes, 

Stem Cells, and Regeneration. 

Date: July 13, 2009. 

Time: 11 a.m. to 1:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Cathy Wedeen, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3213, 

MSC 7808, Bethesda, MD 20892, 301–435– 

1191, wedeenc@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Special 

Topics in Aging and Development. 

Date: July 16, 2009. 

Time: 1 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: John Burch, PhD, 

Scientific Review Officer, National Institute 

of Health, Center for Scientific Review, 6701 

Rockledge Drive, Room 3213, MSC 7808, 

Bethesda, MD 20892, 301–435–1019, 

burchjb@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; RFA–OD– 

09–003 Challenge Grant Panel 11. 

Date: July 20–21, 2009. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Palomar Hotel, 2121 P Street, NW., 

Washington, DC 20037. 

Contact Person: Jerry L. Taylor, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5202, 

MSC 7846, Bethesda, MD 20892, 301–435– 

1175, taylorje@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; RFA OD– 

09–003: Challenge Grants Panel 

Date: July 20–21, 2009. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Mandarin Oriental, 1330 Maryland 

Avenue, SW., Washington, DC 20024. 

Contact Person: Valerie Durrant, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3148, 

MSC 7770, Bethesda, MD 20892, (301) 435– 

3554, durrantv@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 


pwalker on PROD1PC71 with NOTICES